Sun Sep 15 10:08:46 UTC 2024: ## Precede Biosciences’ Epigenomic Liquid Biopsy Shows Promise in Prostate Cancer Treatment

**Barcelona, Spain -** Precede Biosciences, a company specializing in precision medicine, announced promising results from its novel epigenomic liquid biopsy platform at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona. The platform, which analyzes blood samples, demonstrated its ability to accurately detect the expression of prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC).

PSMA is a key target for a new generation of precision medicines in prostate cancer, and its expression is crucial for selecting appropriate treatment options. Current methods for assessing PSMA expression, such as PSMA-PET scans, are not readily available globally, limiting access to targeted therapies. Precede Bio’s liquid biopsy platform offers a minimally invasive alternative, enabling doctors to determine PSMA expression directly from a simple blood draw.

“These data highlight the potential of the Precede Bio platform to resolve important actionable targets from a simple blood draw,” said Carl Barrett, Chief Scientific Officer of Precede Bio. “PSMA is the number one target for the next wave of precision medicines in prostate cancer, and these data support the promise of our platform to inform on therapy selection in this context.”

Precede Bio’s technology holds significant implications for the future of prostate cancer treatment, potentially improving patient outcomes and increasing access to targeted therapies. The company plans to continue collaborating with leading academics and drug developers to advance this research and expand its platform to other high-value targets, including DLL3 and STEAP1.

“We look forward to continuing to work with leading academics and drug developers to advance this important work, and at the same time to continue our work on other high-value targets, such as DLL3 and STEAP1, all with the goal of informing therapy selection for medicines against these targets from the same 1 mL of plasma,” Barrett concluded.

Read More